Variables | Overall response rate | Progression free survival | Overall survival | |||
---|---|---|---|---|---|---|
n (%) | P | HR (95% CI) | P | HR (95% CI) | P | |
Age, years | ||||||
 < 50 (n = 157) | 66 (42.0) | 0.113 | reference |  | reference |  |
 ≥ 50 (n = 198) | 67 (33.8) |  | 1.091 (0.875–1.362) | 0.439 | 1.050 (0.722–1.527) | 0.797 |
Menopausal status | ||||||
 Premenopause (n = 186) | 71 (38.2) | 0.773 | reference |  | reference |  |
 Postmenopause (n = 169) | 62 (36.7) |  | 1.012 (0.812–1.260) | 0.917 | 1.002 (0.691–1.452) | 0.994 |
Body mass index, kg/m2 | ||||||
 < 18.5 (n = 192) | 61 (31.8) | 0.003a | 1.659 (1.160–2.372) | 0.003 | 1.598 (1.035–2.466) | 0.034 |
 18.5–24.9 (n = 50) | 15 (30.0) |  | 1.463 (1.139–1.879) | 0.003 | 2.571 (1.441–4.587) | 0.001 |
 ≥ 25 (n = 113) | 57 (50.4) |  | reference |  | reference |  |
Patient group | ||||||
 Primary (n = 63) | 22 (34.9) | 0.646 | reference |  | reference |  |
 Persistent/recurrent (n = 292) | 111 (38.0) |  | 0.772 (0.582–1.025) | 0.073 | 0.707 (0.436–1.149) | 0.162 |
Initial FIGO stages (n = 351) | ||||||
 I-II (n = 164) | 66 (40.2) | 0.395 | reference |  | reference |  |
 III-IV (n = 187) | 67 (35.8) |  | 1.294 (1.037–1.617) | 0.023 | 0.915 (0.629–1.329) | 0.640 |
Histopathology | ||||||
 Non-SCC (n = 146) | 60 (41.1) | 0.237 | reference |  | reference |  |
 SCC (n = 209) | 73 (34.9) |  | 1.281 (1.023–1.604) | 0.031 | 1.350 (0.920–1.980) | 0.125 |
Disease site before chemotherapy initiation | ||||||
 Locoregional (n = 138) | 56 (40.6) | 0.334 | reference |  | reference |  |
 Distant metastasis (n = 217) | 77 (35.5) |  | 1.353 (1.076–1.702) | 0.010 | 1.971 (1.302–2.983) | 0.001 |
White blood cell count, /mm3 | ||||||
 ≤ 10,000 (n = 300) | 118 (39.3) | 0.089 | reference |  | reference |  |
 > 10,000 (n = 55) | 15 (27.3) |  | 1.683 (1.252–2.263) | 0.001 | 2.339 (1.487–3.678) | < 0.001 |
Neutrophil count, /mm3 | ||||||
 ≤ 7000 (n = 288) | 114 (39.6) | 0.087 | reference |  | reference |  |
 > 7000 (n = 67) | 19 (28.4) |  | 1.673 (1.268–2.208) | < 0.001 | 2.610 (1.706–3.993) | < 0.001 |
Lymphocyte count, /mm3 | ||||||
 ≥ 2000 (n = 44) | 20 (45.5) | 0.242 | reference |  | reference |  |
 < 2000 (n = 311) | 113 (36.3) |  | 1.353 (0.960–1.908) | 0.085 | 1.545 (0.880–2.713) | 0.130 |
NLR | ||||||
 < 3.6 (n = 174) | 77 (44.3) | 0.010b | reference |  | reference |  |
 ≥ 3.6 (n = 181) | 56 (30.9) |  | 1.648 (1.318–2.060) | < 0.001 | 2.759 (1.873–4.065) | < 0.001 |
Monocyte count, /mm3 | ||||||
 ≤ 970 (n = 348) | 132 (37.9) | 0.263 | reference |  | reference |  |
 > 970 (n = 7) | 1 (14.3) |  | 3.038 (1.428–6.462) | 0.004 | 3.641 (0.884–14.994) | 0.074 |
Eosinophil count, /mm3 | ||||||
 ≤ 750 (n = 340) | 126 (37.1) | 0.452 | reference |  | reference |  |
 > 750 (n = 15) | 7 (46.7) |  | 1.207 (0.706–2.064) | 0.491 | 0.679 (0.215–2.138) | 0.508 |
Hemoglobin, g/dL | ||||||
 ≥ 12 (n = 93) | 44 (47.3) | 0.022c | reference |  | reference |  |
 < 12 (n = 262) | 89 (34.0) |  | 1.260 (0.982–1.618) | 0.069 | 1.308 (0.853–2.007) | 0.219 |
Platelet count, /mm3 | ||||||
 ≤ 400,000 (n = 246) | 95 (38.6) | 0.500 | reference |  | reference |  |
 > 400,000 (n = 109) | 38 (37.5) |  | 1.560 (1.232–1.975) | < 0.001 | 1.963 (1.327–2.903) | 0.001 |